ARTICLE IN PRESS



Q1

Alzheimer's

Alzheimer's & Dementia: Translational Research & Clinical Interventions 🔳 (2018) 1-11

Featured Article

The My Active and Healthy Aging information and communications technology platform to detect and prevent frailty in older adults: Randomized control trial design and protocol

Mathew J. Summers^{a,*}, Innocenzo Rainero^b, Alessandro E. Vercelli^c, Georg Aumayr^d, Helios de Rosario^{e,f}, Michaela Mönter^g, Ryuta Kawashima^h, for the My-AHA Consortium[†]

^aSunshine Coast Mind and Neuroscience – Thompson Institute, University of the Sunshine Coast, Queensland, Australia

^cNeuroscience Institute Cavalieri Ottolenghi, Department of Neuroscience, University of Torino, Italy ^dJohanniter Österreich Ausbildung und Forschung gem, GmbH, Department Research and Innovation, Vienna, Austria

anniter Osterreich Ausbildung und Forschung gem, GmbH, Department Research and Innovation, Vienna, Austria ^eInstituto de Biomecánica de Valencia, Universitat Politècnica de València, Valencia, Spain

futo de Biomecanica de Valencia, Universital Politecnica de Valencia, Valencia, ^fCIBER de Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN), Spain

^gGestió Socio Sanitaria al Mediterrani (GESMED), Válencia, Spain

^hInstitute of Development, Aging and Cancer Research (IDAC), Tohoku University, Sendai, Japan

Abstract

Frailty increases the risk of poor health outcomes, disability, hospitalization, and death in older adults and affects 7%-12% of the aging population. Secondary impacts of frailty on psychological health and socialization are significant negative contributors to poor outcomes for frail older adults. The My Active and Healthy Aging (My-AHA) consortium has developed an information and communications technology-based platform to support active and healthy aging through early detection of prefrailty and provision of individually tailored interventions, targeting multidomain risks for frailty across physical activity, cognitive activity, diet and nutrition, sleep, and psychosocial activities. Six hundred adults aged 60 years and older will be recruited to participate in a multinational, multisite 18-month randomized controlled trial to test the efficacy of the My-AHA platform to detect prefrailty and the efficacy of individually tailored interventions to prevent development of clinical frailty in this cohort. A total of 10 centers from Italy, Germany, Austria, Spain, United Kingdom, Belgium, Sweden, Japan, South Korea, and Australia will participate in the randomized controlled trial. Pilot testing (Alpha Wave) of the My-AHA platform and all ancillary systems has been completed with a small group of older adults in Europe with the full randomized controlled trial scheduled to commence in 2018. The My-AHA study will expand the understanding of antecedent risk factors for clinical frailty so as to deliver targeted interventions to adults with prefrailty. Through the use of an information and communications technology platform that can connect with multiple devices within the older adult's own home, the My-AHA platform is designed to measure an individual's risk factors for frailty across multiple domains and then deliver personalized domain-specific

[†]the My-AHA Consortium: Vercelli, A.E., Rainero, I., Caglio, M., Car-bone, C., & Rubino, E. (University of Torino, Italy); Sousa, I., Vasconcelos, M.J.M., Madureira, P., Ribeiro, J., & Cardoso, N. (Fraunhofer Portugal AI-COS, Porto, Portugal); Giannouli, E., & Zijlstra, W. (German Sport Univer-sity Cologne, Germany); Alonso, S., & Mönter, M. (Gestió Socio Sanitaria al Mediterrani); Schnieder, S., Roelen, S.D., Kächele, L. & Krajewski, J. (Institut für Experimentelle Psychophysiologie GmbH, Germany); de Ro-sario, H., Laparra, J., Serrano, J.F., Medina, E., López, A., Pedrero, J.F., & Martínez, Ú. (Instituto de Biomecanica Valencia, Spain); Bazzani, M., Cogerino, C., Toso, G.M., Tommasone, G., Frisello, A. (Istituoto Superiore Mario Boella Sulle Tecnologie Dell'informazione e Delle Telecomunica-zioni, Italy); Aumayr, G, Haider, G., Bleier, D., Sturm, N. (Johanniter Oster-

reich Ausbildung und Forschung Gemeinnutzige, Austria); Kaartinen, N., Kern, A. (KAASA Solution); Bandelow, S., & Niederstrasser, N.G. (Loughborough University, UK); Vaziri, D., Tabatabaei, A., Gouverneur, P., Lagodzinski, P., Wieching, R., Grzegorek, M., Shariat Yazdi, H., Shirahama, K., & Wulf, V. (University of Siegen, Germany); Cho, Y. (Seoul National University, Republic of Korea); Kawashima, R., Burin, D., & Nouchi, R. (Tohoku University, Japan); Summers, M.J. (University of the Sunshine Coast, Australia); Ciferri, L. (International University of Japan, Japan). *Corresponding author. Tel.: +61 07 5456 3758; Fax:

E-mail address: msummers@usc.edu.au

https://doi.org/10.1016/j.trci.2018.06.004

2352-8737/© 2018 Published by Elsevier Inc. on behalf of the Alzheimer's Association. This is an open access article under the CC BY-NC-ND license (http:// creativecommons.org/licenses/by-nc-nd/4.0/).

^bAging, Brain and Memory Clinic, Department of Neuroscience, University of Torino, Italy

2

ARTICLE IN PRESS

M.J. Summers et al. / Alzheimer's & Dementia: Translational Research & Clinical Interventions 🔳 (2018) 1-11

interventions to the individual. The My-AHA platform is technology-agnostic, enabling the integration of new devices and sensor platforms as they emerge. © 2018 Published by Elsevier Inc. on behalf of the Alzheimer's Association. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Frailty; Randomized control trial; Cognition; Physical activity; Mood; Social activity; Nutrition; Older adults

1. Introduction

Keywords:

Frailty is a precursor of and contributor to age-related dis-121 eases [1-5] affecting 7%–12% of the adults aged 65 years 122 and older [5], with the occurrence of frailty increasing 123 with age and potentially reaching a prevalence of 45% in 124 those aged older than 85 years [6,7]. It has been suggested 125 that frailty develops when age-associated degenerative pro-126 cesses overwhelm reserve capacity and plasticity processes 127 that maintain function of the nervous system and other phys-128 129 iologic systems [5,8,9]. Overall, frailty represents the 130 vulnerability of aged population to adverse events as the 131 result of the subtle and progressive metabolic and physical 132 changes. Frailty confers a significantly increased risk for 133 poor health outcomes, incident disability, hospitalization, 134 and mortality [7,10-14]. Older adults experiencing frailty 135 are not acutely medically ill but are in a state of 136 compromised function and capacity arising from a 137 reduction in reserve capacity across multiple systems [15]. 138 This loss of reserve capacity places the individual in a state 139 that is approaching the physiological threshold for symp-140 141 tomatic clinical failure [15]. Therefore, frailty refers to a 142 state of reduced physiological function and capacity rather 143 than to a disease or clinical condition. An older adult in a 144 state of frailty is at increased risk of developing secondary 145 diseases, which then in turn exacerbate the level of frailty 146 experienced [4]. A frail older adult can be conceived of as 147 continually performing at his/her maximum capacity 148 without additional reserves to cope with additional stressors. 149 At the highest level of frailty, the person is increasingly 150 dependent on caregivers, highlighting the social impact of 151 152 frailty as the person progressively loses autonomy. This 153 loss of autonomy is associated with increased need for assis-154 tance with mobility, self-care, and activities of daily living, 155 with an associated progressive loss of self-confidence, leading to social isolation, reduced physical activity, progressive isolation, and decreased social interaction, further exacerbating the level of frailty experienced by the individual. Therefore, early identification and intervention of frailty is 160 essential to prevent this deterioration. 161

The clinical diagnosis of frailty is based on the presence of 162 symptoms of physical weakness (including weak muscle 163 strength, slow gait speed, unintentional weight loss, malnutri-164 165 tion or comorbidity, exhaustion, and low physical activity). 166 The diagnosis of frailty requires the presence of three or 167 more symptoms of the following: shrinking (weight loss or 168 sarcopenia), muscle weakness; poor energy and endurance, 169 motor slowing, and/or reduced level of physical activity [5]. 170

The presence of three or more of these frailty criteria in an older (>65 years) adult constitutes clinical frailty [5]. Individuals presenting with one or two symptoms are considered to be in a prefrail stage [16]. The prefrail stage (1-2 Fried et al [5] criteria) identifies a subset at high risk of progressing to frailty.

171 172

173 174

175

176

177 178

179

180

181

182

183

184

185

186

187

188

189

190

191

192

193

194

195

196

197

198

199

200

201

202

203

204

205

206

207

208

209

210

211

212

213

214

215

216

217

218

219

220

221

222

223

224

225

226

227

228

229

230

231

A fundamental weakness of current clinical frailty criteria [5] is that they remain specific to physical frailty and do not encompass the potential for frailty in other domains (e.g., cognitive, psychological, social, and so forth). Hence, the clinical criteria do not fully reflect the theoretical construct of frailty as a weakness in capacity across multiple systems. An additional challenge to conceptualizing prefrailty is in the relationship between frailty and other aging-related diagnostic constructs (e.g., preclinical dementia, preclinical Parkinson's disease, mild cognitive impairment [MCI], and so forth). The construct of frailty refers to a state of compromised function and capacity arising from a reduction in reserve capacity across multiple systems, creating conceptualization challenges in differentiating frailty from other aging-related syndromes involving a loss of function and capacity. For example, MCI [17-19] is a preclinical syndrome of dementia marked by subclinical cognitive impairments. The more recently described phase of preclinical dementia [20] precedes MCI and is marked by biological changes in the brain associated with later development of MCI and dementia. Neither preclinical dementia nor MCI encompasses frailty as a symptom. Similar phases of preclinical decline or deficits are also observed with various psychological and psychiatric conditions, including schizophrenia, bipolar disorders, as well as mood disturbances and various anxiety-related disorders. If frailty is considered to represent a state of vulnerability in an aging individual to adverse events as a result of subtle and progressive metabolic and physical changes, then the construct of frailty represents either: (1) a fully independent diagnostic entity; or, (2) an umbrella term encompassing all aging-related vulnerabilities, from which specific diagnostic constructs emerge (e.g., MCI). The relationship between frailty and other aging-related disorders is an important consideration that ultimately determines the clinical features of frailty and prefrailty. If frailty is considered to be an umbrella term, then the diagnostic features for specific conditions can be incorporated into frailty subtypes. If, however, frailty is considered to be independent of other agingrelated disorders, then the presence of clinical features of other aging-related disorders precludes a diagnosis of frailty.

Download English Version:

https://daneshyari.com/en/article/8680479

Download Persian Version:

https://daneshyari.com/article/8680479

Daneshyari.com